Brief: Medicenna Presents Promising Clinical Data From Phase 2B Recurrent Glioblastoma Trial Of MDNA55
07/02/2019 12:05
Feb 7 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS PROMISING CLINICAL DATA FROM PHASE 2B
RECURRENT GLIOBLASTOMA TRIAL OF MDNA55
* MEDICENNA THERAPEUTICS CORP - "STRONG INTERIM SURVIVAL
TREND
(15.2 VERSUS 8.5 MONTHS) EMERGING IN IL4R POSITIVE PATIENTS"
* MEDICENNA THERAPEUTICS - ENROLMENT IN SECOND HALF OF STUDY
INCORPORATING A HIGHER DOSE OF MDNA55 IS EXPECTED TO BE
COMPLETED IN NEXT COUPLE OF MONTHS
* MEDICENNA THERAPEUTICS CORP - TOP-LINE RESULTS FROM STUDY
EXPECTED IN MID-2019.
Source text for Eikon: ID:nCNWsDkQLa
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsCanada's Medicenna Q1 net loss slightly widens on smaller fair value gain
Brief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer